Loading
Search products, companies, tests, and guides — go from query to quote request in one place.
Tests
A proprietary chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma on the Abbott Alinity i system. The presence of IgM antibodies may be associated with recent infection or may assist with the evaluation of disease course.
Tests
A proprietary chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgG antibodies to SARS-CoV-2 in human serum and plasma on the Abbott ARCHITECT i system. The persistence of immunoglobulin class G (IgG) antibodies may identify people who have been infected in the past, recovered from the illness, and possibly developed immunity.
Tests
A chemiluminescent microparticle immunoassay (CMIA) used for the qualitative detection of IgM antibodies to SARS-CoV-2 in human serum and plasma on the Abbott ARCHITECT i system. The presence of IgM antibodies may be associated with recent infection or may assist with the evaluation of disease course.
Article
Research record from Int J Mol Sci, 2026-05-14. PMID 42196372.
Article
Research record from Vaccines (Basel), 2026-09-15. PMID 42797632.
Article
Research record from Clin Microbiol Infect, 2026-03-27. PMID 41905558.
Article
Research record from Infect Dis Ther, 2026-04-04. PMID 41934527.
Article
Research record from Diagnostics (Basel), 2026-04-20. PMID 42072850.
Tests
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgA antibodies against SARS-CoV-2 using the S1 domain of the spike protein.
Tests
A proprietary enzyme-linked immunosorbent assay for semi-quantitative detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein, including the receptor binding domain (RBD).
Tests
A proprietary enzyme-linked immunosorbent assay for quantitative detection of IgG antibodies against SARS-CoV-2 using the S1 domain of the spike protein, including the receptor binding domain (RBD).
Glossary Term
Validation evidence that an assay detects the range of variants, genotypes, or serotypes it claims to cover. For evolving targets such as influenza or SARS-CoV-2, inclusivity statements carry a validation date and should be checked against circulating variant lists at procurement time.
